PurposeTo evaluate the relationship between levels of total testosterone and total prostate-specific antigen (PSA) in healthy men with PSA<4 ng/mL.Materials and MethodsThe study comprised 179 men with a mean age of 59.19±12 years who visited Osmaniye State Hospital, Osmaniye, Turkey, between January 2006 and January 2007 for a routine checkup. The patients were divided into two subgroups: patients with PSA<2.5 mg/ml (group I, n=160 patients) and patients with PSA of 2.5 to 4 ng/mL (group II, n=19 patients). The relationship between PSA and testosterone levels was investigated in both groups and in patients aged <60 years. The mean testosterone level was calculated for patients aged <50 years and was compared with the mean value of patients aged ≥50 years.ResultsIn all patients, the mean values for serum PSA and total testosterone were 1.27±0.88 ng/mL and 404.04±158.86 ng/mL, respectively. No correlation was detected between serum PSA and testosterone levels in either subgroup (group I, r=0.072, p=0.363; group II, r=0.031, p=0.900) or in patients aged <60 years (r=0.032, p=0.72). The mean values of testosterone in patients aged ≥50 years and in patients aged <50 years were 417.01±163.35 and 344.16±120.21 ng/dL, respectively (p=0.02).ConclusionsNo impact of testosterone was found on the PSA level in healthy men with PSA <4 ng/mL. Therefore, a high serum testosterone level may not mandate adjustment of PSA values. This serum sex hormone showed a significant increment after the age of 50 years. Further studies including a larger number of patients should be carried out to confirm these findings.
Objective: Hemoglobinopathy is one of the most widespread inherited disorders in Turkey and preventable with premarital screening programs. The aim of this study was determining the prevalence of hemoglobinopathies in Kadirli and discussing the necessity of premarital screening in this prevalent region by evaluating the results of premarital screening that is compulsory for all couples before marriage. Methods: This study was retrospectively conducted between January and November 2013 in Kadirli State Hospital. The results of all couples who applied for premarital screening (n=1994) were included the study. Additionally, screening results of 139 patients, who were admitted to the hospital without premarital screening, were also included in the study. Totally, 2133 screenings were included in this study. All samples were measured by high-performance liquid chromatography (HPLC) to determine haemoglobinopathies. Results: The number of beta-thalassemia trait was 98 (%4,91) in 1994 premarital screening. Hemoglobin D was the most common abnormal hemoglobin by 5 trait (%0.46) and 1 homozygote (%0.09). Hemoglobin S-Trait was also detected in 2 patient, as well as one HbE trait. The frequency of beta-thalassemia trait was 10 (%7.19) in 139 patients who were admitted to the hospital without premarital screening. None of those had variant hemoglobin type. Conclusion: According to the results of premarital screening, Kadirli beta-thalassemia trait was observed to be over the average of Turkey, while it was below the average of Çukurova and the Mediterranean region where Kadirli is located in. The results showed that premarital hemoglobinopathy screening should be kept being applied for all partners planning to get married in Kadirli. Additionally, all these people with variant Hb traits should be evaluated by further molecular genetic analysis in terms of its diversity of hemoglobinopathies.
Objective:We aimed to evaluate the relationship between serum total testosterone and total prostate specific antigen (TPSA) levels in healthy men from two different regions of Turkey.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.